$RGBP Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. These studies were conducted at ChemDiv Inc., the Company's contract research organization. https://www.prnewswire.com/news-releases/regen-biopharma-incs-medicinal-chemistry-program-has-identified-additional-compounds-that-activate-nr2f6-669711503.html?utm_content=buffer6dcba&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer